Comprehensive assessment beyond eosinophils in eosinophilic esophagitis: an updated network meta-analysis
This study suggests that Dupilumab 300mg qw might be the best performing agent for induction of clinical improvement (the primary endpoint) and BODT might be the most efficacious agents for histological and endoscopic improvement (the secondary endpoint). This could provide evidence for clinical therapy strategy for EoE patients.
Authors
- Shuliang Zhao (ORCID: https://orcid.org/0000-0003-2994-5414)
- Yangbao Lyu
- Zhi Wu (ORCID: https://orcid.org/0009-0002-8703-0706)
- Yue Zhang (ORCID: https://orcid.org/0000-0002-0603-6536)
- Yuming Zhou
Institutions
- Shanghai Jiao Tong University (CN)
- Renji Hospital (CN)
- State Key Laboratory of Oncogene and Related Genes (CN)
Publication Details
- Journal
- BMC Gastroenterology
- Published
- 2025-11-21
- DOI
- https://doi.org/10.1186/s12876-025-04434-5
- Primary Topic
- Eosinophilic Esophagitis
- Type
- article
- Field-Weighted Citation Impact
- 0.00